81,000 Shares in AxoGen, Inc. $AXGN Purchased by Swiss National Bank

Swiss National Bank acquired a new position in AxoGen, Inc. (NASDAQ:AXGN) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 81,000 shares of the medical equipment provider’s stock, valued at approximately $1,498,000. Swiss National Bank owned approximately 0.18% of AxoGen as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. State of Wyoming acquired a new stake in shares of AxoGen in the fourth quarter valued at approximately $31,000. Fifth Third Bancorp bought a new position in AxoGen during the 1st quarter worth $92,000. GAMMA Investing LLC raised its holdings in AxoGen by 3,884.6% in the 1st quarter. GAMMA Investing LLC now owns 5,698 shares of the medical equipment provider’s stock valued at $105,000 after acquiring an additional 5,555 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of AxoGen during the 1st quarter valued at $146,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of AxoGen during the 1st quarter worth $150,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AXGN. Canaccord Genuity Group dropped their price target on AxoGen from $26.00 to $24.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th. Wall Street Zen upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $26.00.

AxoGen Trading Up 2.7%

AXGN opened at $16.26 on Monday. The company’s 50 day moving average is $12.38 and its 200-day moving average is $14.44. AxoGen, Inc. has a 1-year low of $9.22 and a 1-year high of $21.00. The company has a current ratio of 4.14, a quick ratio of 2.67 and a debt-to-equity ratio of 0.59. The company has a market cap of $748.12 million, a P/E ratio of -162.58 and a beta of 1.00.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.